Description of Invention: Ovarian cancer is one of the most common forms of neoplasia in women. Although advanced ovarian cancer has only a 20-30% survival rate, an estimated 90% of cases are effectively treated when detected early. However, few symptoms are associated with early ovarian cancer, and approximately 25% of ovarian cancer cases are diagnosed before it metastasizes. Utilizing SAGE analysis, a unique set of ovarian cancer biomarkers has been identified that are highly expressed in ovarian epithelial tumor cells in comparison to normal ovarian epithelial cells. A better knowledge of the mechanisms underlying ovarian tumorigenesis will likely result in the development of novel approaches for the diagnosis and therapy of this deadly disease.
Method to diagnose ovarian cancer
Methods to treat patients with compositions that inhibit ovarian biomarkers such as siRNA
Development Status: The technology is currently in the pre-clinical stage of development.
KJ Hewitt, R Agarwal, PJ Morin. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006 Jul 12;6:186. [ PubMed abs ]
PJ Morin. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005 Nov 1;65(21):9603-9606. [ PubMed abs ]
R Agarwal, T D'Souza, PJ Morin. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005 Aug 15;65(16):7378-7385. [ PubMed abs ]
CD Hough, CA Sherman-Baust, ES Pizer, PJ Morin. Use of SAGE to study gene expression in ovarian cancer. American Association for Cancer Research, 9th Annual Meeting, April 10-14, 1999, Philadelphia, Pennsylvania.
Licensing Status: Available for licensing.
Portfolios: Cancer Cancer - Diagnostics Rare Diseases
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4633 Fax: 301-402-0220